FTC's GoodRx case 'a cautionary tale' for organizations processing sensitive personal data
The U.S. Federal Trade Commission's "first-of-its-kind" enforcement action against U.S. health care company GoodRx has important takeaways for privacy programs that handle health-related data. It also signals an increase in the FTC's use of its unfairness authority in privacy cases, IAPP Managing Director, Washington, D.C., Cobun Zweifel-Keegan, CIPP/US, CIPM, and Westin Research Fellow Amy Olivero write.